Former GW Pharmaceuticals President Joins Lexaria

 Lexaria Bioscience (Nasdaq:LEXX) has appointed the former President of GW Pharmaceuticals USA, Julian Gangolli, as a Strategic Advisor.

Mr. Gangolli said: “The potential of Lexaria’s disruptive drug delivery technology is significant and I hope to assist Lexaria in its commercial development of DehydraTECH for multiple applications.”


  • Prior to being acquired by Jazz Pharmaceuticals, GW Pharmaceuticals established a world-leading cannabinoid science platform including an innovative pipeline of early and late-stage cannabinoid product candidates.
  • Gangolli brings extensive pharmaceutical experience to the role of Strategic Advisor. He oversaw FDA approval of the first and only pure cannabidiol (“CBD”) drug ever approved by the FDA, Epidiolex®, and its subsequent successful commercialization in the USA.

Lexaria has stated it will intensify its focus on the commercial execution of DehydraTECH technology portfolio during 2023.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Former GW Pharmaceuticals President Joins Lexaria

Editor Prism MarketView